Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7589831 |
Synonyms | |
Therapy Description |
RO7589831 covalently binds to and inhibits WRN, resulting in decreased ATPase and helicase and activity, which potentially induces DNA damage and cell cycle arrest and leads to inhibition of tumor growth (PMID: 38658751). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7589831 | RO-7589831|RO 7589831|VVD-133214|RG 6457|RG-6457|VVD-214 | RO7589831 covalently binds to and inhibits WRN, resulting in decreased ATPase and helicase and activity, which potentially induces DNA damage and cell cycle arrest and leads to inhibition of tumor growth (PMID: 38658751). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06004245 | Phase I | RO7589831 | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | DNK | CAN | BEL | 0 |